Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Ramzi A Ockaili"'
Autor:
Ramzi A Ockaili, Chad Cain, Arun Samidurai, Rakesh C. Kukreja, Donatas Kraskauskas, Scott M. Filippone, Sean K Roh, Anindita Das
Publikováno v:
STAR Protocols
STAR Protocols, Vol 2, Iss 3, Pp 100772-(2021)
STAR Protocols, Vol 2, Iss 3, Pp 100772-(2021)
Summary We developed a preclinical model of myocardial ischemia/reperfusion (I/R) injury in conscious diabetic rabbits to identify an early pharmacological intervention for patients with diabetes and acute myocardial infarction (AMI). Here, we descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbf64663dace427e838c2eee6e0d4a84
https://pubmed.ncbi.nlm.nih.gov/34485939
https://pubmed.ncbi.nlm.nih.gov/34485939
Autor:
Scott M. Filippone, Sean K Roh, Donatas Kraskauskas, Rakesh C. Kukreja, Ramzi A Ockaili, Anindita Das, Chad Cain, Arun Samidurai
Publikováno v:
iScience
iScience, Vol 23, Iss 12, Pp 101863-(2020)
iScience, Vol 23, Iss 12, Pp 101863-(2020)
Summary Persistent activation of mTOR (mammalian target of rapamycin) in diabetes increases the vulnerability of the heart to ischemia/reperfusion (I/R) injury. We show here that infusion of rapamycin (mTOR inhibitor) at reperfusion following ischemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8df298530446a310cb99309f5b400d5
https://pubmed.ncbi.nlm.nih.gov/33319180
https://pubmed.ncbi.nlm.nih.gov/33319180
Autor:
Adolfo G Mauro, Siddhartha S. Ghosh, Vinh Q Chau, Fadi N Salloum, Francisco Romeo, Teja Devarakonda, Juan Torrado, John A. Nestler, Chad Cain, Anindita Das, Ramzi A Ockaili
Publikováno v:
Journal of the American College of Cardiology. 72(19)
Background Sacubitril/valsartan (SAC/VAL) is approved by the U.S. Food and Drug Administration for heart failure with reduced ejection fraction (HFrEF). Objectives This study investigated the effects of SAC/VAL on acute myocardial infarction (MI) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1d848e85488e566c0e28c3c2cd27e7
https://pubmed.ncbi.nlm.nih.gov/30384892
https://pubmed.ncbi.nlm.nih.gov/30384892
Autor:
Arun Samidurai, Chad Cain, Ramzi A Ockaili, Scott M. Filippone, Rakesh C. Kukreja, Anindita Das
Publikováno v:
The FASEB Journal. 32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab3866278f3fffe0717f31921a2e6268
https://doi.org/10.1096/fasebj.2018.32.1_supplement.580.16
https://doi.org/10.1096/fasebj.2018.32.1_supplement.580.16
Autor:
Juan Torrado, Chad Cain, Adolfo G Mauro, Ramzi A Ockaili, Francisco Romeo, John Nestler, Teja Devarakonda, Anindita Das, Fadi N Salloum
Publikováno v:
Circulation. 136
Background: Sacubitril/Valsartan (SAC/VAL), a drug combining a neprilysin inhibitor and an angiotensin receptor blocker, was shown to reduce myocardial infarct size and left ventricular (LV) dysfunction in preclinical models of myocardial infarction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd46b428e8bb4496d85ab2eefb03e428
https://doi.org/10.1161/circ.136.suppl_1.24021
https://doi.org/10.1161/circ.136.suppl_1.24021
Autor:
Nicholas N Hoke, Vinh Q Chau, Ramzi A Ockaili, Anindita Das, Johannes-Peter Stasch, Fadi N Salloum, Rakesh C. Kukreja, Arun Samidurai
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 302:H1347-H1354
Cinaciguat (BAY 58–2667) is a novel nitric oxide (NO)-independent activator of soluble guanylate cyclase (sGC), which induces cGMP-generation and vasodilation in diseased vessels. We tested the hypothesis that cinaciguat might trigger protection ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::832f197d25f9685d6a8a2e5a96fe3df0
https://doi.org/10.1152/ajpheart.00544.2011
https://doi.org/10.1152/ajpheart.00544.2011
Autor:
Matthew A. Movsesian, Judith Krall, Vincent A. Florio, Rakesh C. Kukreja, Fabrice Vandeput, Fadi N Salloum, Ramzi A Ockaili, Sharron H. Francis, Jackie D. Corbin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 330:884-891
In mouse models of cardiac disease, the type 5 (PDE5)-selective cyclic nucleotide phosphodiesterase inhibitor sildenafil has antihypertrophic and cardioprotective effects attributable to the inhibition of cGMP hydrolysis. To investigate the relevance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b43bf9519d6acda2d35649f2a5a0b36a
https://doi.org/10.1124/jpet.109.154468
https://doi.org/10.1124/jpet.109.154468
Autor:
Michael Wittkamp, Chang Yin, Ramzi A Ockaili, Amit K. Kukreja, Fadi N Salloum, Xiaoyin Wang, Vijay R. Marwaha, John Hawkins, Rakesh C. Kukreja, Anindita Das, Patrick W. Fisher, Yvonne A Bremer, Lei Xi, Eric Chou
Publikováno v:
Vascular Pharmacology. 42:219-232
The phosphodiesterase type-5 (PDE5) inhibitor, sildenafil, is the first drug developed for treatment of erectile dysfunction in patients. Experimental data in animals show that sildenafil has a preconditioning-like cardioprotective effect against isc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41654323596d41076bb7d0dd7ddb0bfb
https://doi.org/10.1016/j.vph.2005.02.010
https://doi.org/10.1016/j.vph.2005.02.010
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 286:H1455-H1460
Sildenafil citrate (Viagra) is the most widely used pharmacological drug for treating erectile dysfunction in men. It has potent cardioprotective effects against ischemia-reperfusion injury via nitric oxide and opening of mitochondrial ATP-sensitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63102f6d008583639188d3fae67c422
https://doi.org/10.1152/ajpheart.01040.2003
https://doi.org/10.1152/ajpheart.01040.2003
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 283:H1263-H1269
Sildenafil citrate (Viagra) is the pharmacological agent used to treat erectile dysfunction in men. Because this drug has a vasodilatory effect, we hypothesized that such an action may induce a preconditioning-like cardioprotective effect via opening
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95e5060b028e37d56552455976273d5a
https://doi.org/10.1152/ajpheart.00324.2002
https://doi.org/10.1152/ajpheart.00324.2002